Please assess the completion status of the following clinical trial:

Trial Title: Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject has a confirmed diagnosis of cystic fibrosis~* detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of the lung (from day -28)~* informed consent of the patients or parents~* subject is older than 7 years~* subject is able to comply with the inhalation procedures and nasal lavage procedures scheduled in the protocol~* women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol~Exclusion Criteria:~* subject has a critical condition defined as: FEV1 \< 30% and / or SaO2 \< 93% without O2-substitution; need of O2-substitution~* subject had an ENT surgery within 3 months prior to study~* subject shows signs of nasal bleeding~* subject has an ear drum perforation~* subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy against pseudomonas aerug.~* subject is unlikely to comply with the procedures scheduled in the protocol~* subject has a known allergic reaction to the medication~* subject is pregnant or breastfeeding~* subject participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study.~* systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the inclusion and during the study~* if serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to withdraw the participation in the study.~* progressed renal insufficiency~* severe damage of the N. acusticus~* dizziness (potential damage of. N. vestibularis)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin 80 mg (Type: ACTIVE_COMPARATOR): applied once daily via Pari Sinus nebulizer
- isotonic saline (Type: PLACEBO_COMPARATOR): applied once daily via Pari Sinus nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).